

Appl. No. 09/676,502

13. (Amended) Pharmaceutical composition useful in the treatment of asthma, said composition comprising an amount of an extract obtained from the plant *Murraya koenigii* effective for treating asthma together with at least one pharmaceutically acceptable additive.

14. (Amended) The composition as claimed in claim 13, wherein the at least one additive is a powder or extract of at least one plant selected from the group consisting of *M. paniculata* Linn, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A. vasica* Nees, and *E. hirta*.

15. (Amended) The composition as claimed in claim 13, wherein the composition comprises 80-100 mg of *M. paniculata* Linn, 40-60 mg of *H. abelmoschus*, 38-62 mg of *T. ammi*, 7-13 mg of *S. aromaticum*, 85 - 115 mg of *A. vasica* Nees and 90-110 mg of *E. hirta*.

16. (Amended) The composition as claimed in claim 13, comprising:

M. paniculata Linn. *Syn. M. exotica* 90mg
(KAMINI)

H. abelmoschus 50mg
(JOWAN)

Appl. No. 09/676,502

T. ammi 50mg
(LAVANGA)

S. aromaticum 10mg
(BASAK)

A. vasica Nees 100mg
(PUSITOA)

E. hirta 100mg

M. koinegii
(Suravi Neem) 100mg.

17. (Amended) The composition as claimed in claim 13, wherein the extract of the plant *M. koenegii* is present in the range of 87-105 mg per dose.

20. (Amended) The composition as claimed in claim 13, wherein the extract has active principles having *R_f* values 0.73, 0.60, 0.34 and 0.14 in chloroform and methanol in the ratio 19:1 and *R_f* values 0.60, 0.38, 0.24 and 0.15 in chloroform.

Appl. No. 09/676,502

21. (Amended) The composition as claimed in claim 13, wherein the extract exhibits four peaks having retention times of 3.37, 3.49, 4.0 and 5.69 minutes in high pressure liquid chromatography over octyl decyl silane medium using methanol solvent and detection of absorbance at 254 nm.

Q9

22. (Amended) The composition as claimed in claim 13, wherein the extract obtained from the plant *M. koenigii* exhibits antioxidant activity.

24. (Amended) The method as claimed in claim 23, wherein the lyophilized extract obtained from *Murraya koenigii* is administered along with at least one pharmaceutically acceptable additive for the treatment of asthma.

25. (Amended) The method as claimed in claim 23, wherein the mode of administration is oral for the treatment of mild or acute asthma.

Q10

26. (Amended) The method as claimed in claim 23, wherein the dosage level of the composition is in between 325-600 mg twice daily for the period ranging from 3 to 30 days.

27. (Amended) The method as claimed in claim 23, wherein the dosage level is in between 325-600 mg twice daily for the period ranging from 3 to 15 days for mild asthmatic condition.

Appl. No. 09/676,502

28. (Amended) The method as claimed in claim 24, wherein the additive is at least one selected from the group consisting of *M. paniculate Linn*, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A. vasica Nees* and *E. hirta*.

29. (Amended) The method as claimed in claim 28, wherein the composition comprises 80-100 mg of *M. paniculate Linn*, 40-60 mg of *H. abelmoschus*, 38-62 mg of *T. ammi*, 7-13 mg of *S. aromaticum*, 85-115 mg of *A. vasica Nees*, 90-110 mg of *E. hirta*, along with 87-105 mg of *M. koenegii* per dose.

Q10

30. (Amended) The method as claimed in claim 29, wherein the composition comprises 90 mg of *M. paniculate Linn*, 50 mg of *H. abelmoschus*, 50 mg of *T. ammi*, 10 mg of *S. aromaticum*, 100 mg of *A. vasica Nees*, 100 mg of *E. hirta*, along with 100 mg of *M. koenegii* per dose.

31. (Amended) The method as claimed in claim 24, wherein the composition comprises the additives *M. paniculate Linn*, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A. vasica Nees*, *E. hirta*, and is also effective as an antidiarrheal, antiseptic, carminative, stimulant, antitussive, anti- bronchitis agent and for nourishment.

Appl. No. 09/676, 502

32. (Amended) The method as claimed in claim 28, wherein the additives are obtained from :

bark or root of *M. paniculate* Linn; dried flower buds of *H. abelmoschus*; leaves of *T. ammi*; whole plant parts of *S. aromaticum*; root of *A. vasica* Nees and bark of *E. hirta*.

33. (Amended) An anti-oxidant composition for human beings and animals, said composition comprising an effective amount of an extract obtained from the plant *Murraya koenigii* and optionally at least one pharmaceutically acceptable additive.

Q10
34. (Amended) The composition as claimed in claim 33, wherein at least one additive is present in the composition and is a powder or extract of at least one plant selected from the group consisting of *M. paniculate* Linn, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A. vasica* Nees and *E. hirta*.

35. (Amended) The composition as claimed in claim 34, wherein the composition comprises 80-100 mg of *M. paniculate* Linn, 40-60 mg of *H. abelmoschus*, 38-62 mg of *T. ammi*, 7-13 mg of *S. aromaticum*, 85-115 mg of *A. vasica* Nees, 90-110 mg of *E. hirta*, along with 87-105 mg of *M. koenigii* per dose.

36. (Amended) The composition as claimed in claim 35, wherein the composition comprises 90 mg of *M. paniculate* Linn, 50 mg of *H. abelmoschus*, 50 mg of *T. ammi*, 10 mg of *S. aromaticum*, 100 mg of

Appl. No. 09/676,502

A10
A. *vasica* Nees, 100 mg of *E. hirta*, along with 100 mg of *M. koenegii* per dose.

37. (Amended) The composition as claimed in claim 34, wherein the additives *M. paniculata* Linn, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A. vasica* Nees, *E. hirta* along with *M. koenegii* are used as an antidiarrheal, antiseptic, carminative, stimulant, antitussive, anti- bronchitis agent and nourishment, respectively.

38. (Amended) The composition as claimed in claim 34, wherein the additives are selected from *M. paniculata* Linn, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A. vasica* Nees and *E. hirta*, in the form of bark or root; seed; fruit; dried flower buds; leaves; whole plant; and root and bark, respectively.

A11
Please add the following new claims:

--41. A process for producing an extract comprising:

- i) extracting fresh leaves of *Murraya koenigii* with a hydrocarbon, chlorinated hydrocarbon, ether or ester solvent to obtain a percolate,
- ii) separating the percolate from the leaves, and
- iii) removing the solvent from the percolate to obtain an extract.

Appl. No. 09/676,502

42. The process of claim 41, in which the hydrocarbon or chlorinated hydrocarbon solvent is used.

43. The process of claim 42, in which the hydrocarbon or chlorinated hydrocarbon solvent is selected from the group consisting of petroleum ether having a boiling point from 40 to 80 °C, benzene, pentane, hexane, chloroform, dichloromethane and carbon tetrachloride.

44. The process of claim 41 in which an ether or ester solvent is used.

45. The process of claim 44, in which the ether or ester solvent is selected from the group consisting of diethyl ether, tetrahydrofuran, dioxane, ethyl acetate and ethyl formate.

46. The process of claim 41, in which the extraction is performed for a period from 12 to 16 hours.

47. The process of claim 41, in which the solvent is removed under reduced pressure at a temperature of from 20 to 80 °C.

48. A process for preparing an extract comprising:

i) extracting fresh leaves of *Murraya koenigii* with methanol to obtain a percolate,

Appl. No. 09/676,502

- ii) separating the percolate from the leaves, and
- iii) removing the solvent from the percolate to obtain an extract.

49. The process of claim 48, in which the extraction is performed for a period from 12 to 16 hours.

50. The process of claim 48, in which the solvent is removed under reduced pressure at a temperature of from 20 to 80 °C.

51. An extract of *Murraya koenigii* produced by the process of claim 48, wherein the extract comprises compounds:

Q11

- i) exhibiting thin layer chromatography Rf values in a chloroform:methanol 19:1 solvent of 0.73, 0.60, 0.34 and 0.14;
- ii) exhibiting thin layer chromatography Rf values in a chloroform solvent of 0.60, 0.38, 0.24 and 0.15;
- iii) having activity in inhibiting arachidonic acid oxidation by neutrophils.

52. The method as claimed in claim 27, wherein the dosage level is in between 325-600 mg twice daily for the period ranging from 15 - 30 days for acute asthmatic condition.--
